WallStreetZenWallStreetZen

NASDAQ: RLMD
Relmada Therapeutics Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their RLMD stock forecasts and price targets.

Forecast return on equity

Is RLMD forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
35.5%

Forecast return on assets

Is RLMD forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

RLMD revenue forecast

What is RLMD's revenue in the next 2 years based on estimates from 1 analyst?
Avg 1 year Forecast
$26.6M
Avg 2 year Forecast
$189.4M

RLMD vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RLMD$3.91N/AN/A
GLYC$1.84$10.00+444.96%Buy
PDSB$3.20$17.33+441.66%Strong Buy
SEER$1.81N/AN/A
NVCT$6.59N/AN/A

Relmada Therapeutics Stock Forecast FAQ

What is RLMD's revenue growth forecast for 2027-2028?

(NASDAQ: RLMD) Relmada Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.57%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.16%.

Relmada Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast RLMD's revenue for 2027 to be $802,633,773, with the lowest RLMD revenue forecast at $802,633,773, and the highest RLMD revenue forecast at $802,633,773.

In 2028, RLMD is forecast to generate $5,714,993,859 in revenue, with the lowest revenue forecast at $5,714,993,859 and the highest revenue forecast at $5,714,993,859.

If you're new to stock investing, here's how to buy Relmada Therapeutics stock.

What is RLMD's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: RLMD) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is RLMD's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: RLMD) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.